HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that AOAC INTERNATIONAL has approved Bio-Rad’s dd-Check STEC Solution for detecting and confirming virulence genes from Shiga toxin-producing Escherichia coli (STEC), in raw beef trim, fresh spinach and carcass sampling cloths. It is the first Droplet Digital™ PCR method approved by AOAC. The approval of the method for confirmation signifies that the dd-Check STEC Solution is comparable to the standard reference method for confirmation of STEC.
The dd-Check STEC Solution, evaluated and approved by the AOAC Performance Tested MethodsSM (PTM) Program, uses ddPCR technology to generate thousands of uniform nanoliter-sized droplets that are amplified, read, and analyzed for the colocalization of stx and eae virulence genes in a single bacterium (true positive), differentiating it from samples where virulence genes are from two different bacteria (false positive).
Brad Stawick, Senior Director of AOAC Research Institute, explained the significance of method validation: “The Performance Tested Method Program provides a rigorous third-party evaluation of test kits and other proprietary methods, ensuring that they are fit for their intended purpose and perform as claimed. This includes validation of methods based on innovative technologies, such as the recently approved Bio-Rad test kit for Shiga toxin-producing Escherichia coli (STEC) using droplet digital polymerase chain reaction (ddPCR)”
Simon May, EVP and President of Bio-Rad’s Life Science Group commented: “The dd-Check STEC assay demonstrates Bio-Rad's dedication to delivering innovative solutions for food safety testing. The rigorous and thorough standards set by AOAC validation align with our aim to provide top-tier products for our customers, and we’re proud to be playing a role in driving the transformation of STEC testing.”
To learn more about the dd-Check STEC Solution, visit bio-rad.com/ddcheck.
BIO-RAD and Droplet Digital are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Wendy Lauer
+1 510-741-5653
wendy_lauer@bio-rad.com